Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19432667 | 0.85 | BRD9 (0.32) | CYP17A1GSK3BDYRK1AMAPKAPK2IDO1 | |
| SCHEMBL11890435 | 0.82 | BRD9 (0.40) | CYP17A1HDAC1SCDIDO1BRD9 | |
| SCHEMBL25321588 | 0.81 | CYP17A1 (0.33) | CYP17A1DGAT1GSK3BDYRK1AMAPKAPK2 | |
| SCHEMBL25326471 | 0.77 | MAPKAPK2 (0.33) | CYP17A1DGAT1GSK3BDYRK1AMAPKAPK2 | |
| SCHEMBL16213587 | 0.77 | GSK3B (0.32) | CYP17A1DGAT1GSK3BDYRK1ASCD | |
| SCHEMBL1593250 | 0.76 | MAPKAPK2 (0.38) | CYP17A1DGAT1GSK3BDYRK1AMAPKAPK2 | |
| SCHEMBL16213623 | 0.76 | GSK3B (0.32) | DGAT1GSK3BDYRK1A | |
| SCHEMBL941272 | 0.75 | FFAR4 (0.36) | DGAT1GSK3BDYRK1AMAPKAPK2 | |
| SCHEMBL29300799 | 0.74 | IDO1 (0.36) | LMNAIDO1 | |
| SCHEMBL29300801 | 0.74 | AAK1 (0.41) | DGAT1GSK3BDYRK1AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| EP-3596072-B1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-06-22 | — | — | EP | disclosed |
| US-11155557-B2 | Pyrazolopyrimidine compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3562809-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-06-09 | — | — | EP | disclosed |
| EP-3145929-B1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-13 | — | — | EP | disclosed |
| EP-3670514-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20190345165-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20150152117-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152117-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-8999998-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999998-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999998-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2448941-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011003065-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011003065-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155557-B2 | Pyrazolopyrimidine compounds and methods of use thereof | JAK2, JAK1, JAK3 | CYP17A1 1116/4885DGAT1 4274/4885GSK3B 761/4885 |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | CYP17A1 1549/4885DGAT1 3757/4885GSK3B 288/4885 |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | CYP17A1 1549/4885DGAT1 3757/4885GSK3B 288/4885 |
| US-20190345165-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | CYP17A1 1116/4885DGAT1 4274/4885GSK3B 761/4885 |
| US-20150152117-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | CYP17A1 1549/4885DGAT1 3757/4885GSK3B 288/4885 |
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | CYP17A1 1549/4885DGAT1 3757/4885GSK3B 288/4885 |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | JAK1, JAK2, JAK3 | CYP17A1 330/4885DGAT1 2633/4885GSK3B 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.